WO2022150644A1 - Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r) - Google Patents

Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r) Download PDF

Info

Publication number
WO2022150644A1
WO2022150644A1 PCT/US2022/011700 US2022011700W WO2022150644A1 WO 2022150644 A1 WO2022150644 A1 WO 2022150644A1 US 2022011700 W US2022011700 W US 2022011700W WO 2022150644 A1 WO2022150644 A1 WO 2022150644A1
Authority
WO
WIPO (PCT)
Prior art keywords
ser
thr
gly
leu
tyr
Prior art date
Application number
PCT/US2022/011700
Other languages
English (en)
Inventor
Paul F. LIZZUL
Original Assignee
Anaptysbio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio, Inc. filed Critical Anaptysbio, Inc.
Publication of WO2022150644A1 publication Critical patent/WO2022150644A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Definitions

  • Acne i.e., acne vulgaris
  • Acne vulgaris is the most common skin condition in the United States, affecting up to 50 million Americans annually. Seven million Americans likely suffer from moderate-to-severe acne annually. Acne usually begins in puberty and affects many adolescents and young adults. Causes of acne include follicular hyperkeratinization, sebum production, presence of Propionibacterium acnes (P. acnes), inflammatory mediators, and androgens. Bhambri et al. J. Drugs in Derm., 8(7): 61618 (2009)). It is also thought that genetics and diet can play a part in the development of acne.
  • Symptoms of acne include comedones (i.e., blackheads and whiteheads) and inflammatory lesions, including papules, pustules, and nodules (i.e., cysts), which are mainly located on sebum-rich regions of the skin, such as face, chest, back, and upper arms.
  • comedones i.e., blackheads and whiteheads
  • inflammatory lesions including papules, pustules, and nodules (i.e., cysts)
  • nodules i.e., cysts
  • therapies include topical therapies, such as retinoids and retinoid-like drugs, antibiotics, benzoyl peroxide, salicylic acid, and azeleic acid, and systemic therapies, such as oral antibiotics, oral contraceptive pills, and isotretinoin.
  • topical therapies such as retinoids and retinoid-like drugs, antibiotics, benzoyl peroxide, salicylic acid, and azeleic acid
  • systemic therapies such as oral antibiotics, oral contraceptive pills, and isotretinoin.
  • these therapies are not all effective for every subject and some can have harmful side effects, including, but not limited to, toxicity of isotretinoin and antibiotic resistance.
  • IL-36 interleukin 36
  • the disclosure futher provides an IL-36R binding agent and composition comprising same for use to treat acne in the described methods.
  • a method of treating acne in a subject comprising inhibiting IL-36 signaling in the subject, thereby treating the acne.
  • Inhibiting IL-36 signaling can be accomplished by any suitable method, such as by preventing IL-36 receptor (IL-36R) from binding to one or more (or all) IL-36 cytokines (e.g., IL-36a, IL-36P, and/or IL-36y).
  • IL-36R IL-36 receptor
  • IL-36 cytokines e.g., IL-36a, IL-36P, and/or IL-36y.
  • the IL-36 cytokines IL-36a, IL-36p, and IL-36y are interleukin-1 (IL-1) family members that bind to the IL-36R (formerly IL-lRrp2 or IL- 1RL2), a receptor of the IL-1R family, and use IL-1 receptor accessory protein (IL-lRAcP) as a coreceptor to stimulate intracellular signals similar to those induced by IL-1 (Towne et al, J.
  • IL-1 receptor accessory protein IL-1 receptor accessory protein
  • IL-1F5 is an IL-1 family member that has been shown to act as an antagonist of IL-36R, and is now referred to as IL-36Ra (Dinarello et al, Nat. Immunol., 11(11): 973 (2010)).
  • the subject can be a mammal, such as a human or non- human primate, with acne.
  • the acne described in the method of the embodiment may be any type of acne, regardless of genotype or phenotype.
  • the acne may be associated with upregulated IL- 36a, IL-36P, and/or IL-36y compared to a normal subject.
  • the subject to be treated can have elevated levels of one or more of IL-36a, IL-36P, and/or IL-36y compared to a normal, non-diseased subject (e.g., elevated levels of one or more of IL-36a, IL- 36b, and/or IL-36y in a tissue (skin or skin lesion) or fluid sample from an affected tissue of the subject as compared to level of the same cytokine(s) from the same type of sample from a non- affected tissue of the same subject or from a normal, non-diseased subject).
  • a normal, non-diseased subject e.g., elevated levels of one or more of IL-36a, IL- 36b, and/or IL-36y in a tissue (skin or skin lesion) or fluid sample from an affected tissue of the subject as compared to level of the same cytokine(s) from the same type of sample from a non- affected tissue of the same subject or from a normal
  • the increased skin expression of the IL-36 cytokine e.g., IL-36a, IL-36P, and/or IL-36y
  • the increased skin expression of the IL-36 cytokine in the sample from the affected tissue s at least about 25% higher (e.g., at least about 30% higher, or at least about 50% higher) than the normal baseline expression of the non- affected sample.
  • the acne may be associated with upregulated TNF-a, IL- 6, and IL-8 expression compared to a normal subject.
  • the acne may be associated with Thl7 activation in skin and/or consequent induction of IL-17-related genes or markers synergistically induced by IL-17 and TNF-a.
  • the acne is resistant or non-responsive to oral and/or topical retinoids, antibiotics, or isotretinoin.
  • the method comprises comparing the expression of at least one of an IL-36 cytokine, IL-36R, or mRNA encoding same in a tissue (skin or skin lesion) or fluid sample from an affected tissue of the subject with a suitable normal control (e.g., the level of the same cytokine(s) or receptor or mRNA from the same type of sample from a non-affected tissue of the same subject or from a normal, non-diseased subject, or average of such expression levels in a population of normal, non-diseased subjects).
  • a suitable normal control e.g., the level of the same cytokine(s) or receptor or mRNA from the same type of sample from a non-affected tissue of the same subject or from a normal, non-diseased subject, or average of such expression levels in a population of normal, non-diseased subjects.
  • the subject is selected for treatement if the expression of the IL-36 cytokine, IL-36R, or mRNA encoding same is increased (e.g., by at least about 20%, 50%, 100%, 200%, or more) in the subject as compared to the normal control.
  • the method can comprise comparing the expression of at least one of an IL-36 cytokine, IL-36R, or mRNA encoding same in a tissue (skin or skin lesion) or fluid sample from an affected tissue of the subject before and after administration of an IL-36 pathway inhibitor; and selecting the subject for treatment when a decrease in expression of at least one of an IL-36 cytokine, IL-36R, or mRNA encoding same is observed after administration of the IL-36 pathway inhibitor as compared to before administration of the IL-36 pathway inhibitor.
  • the subject so selected can, optionally, be treated according to the methods described herein.
  • the IL-36 cytokine and IL-36R protein levels or mRNA levels of the subject can be measured using any suitable method known in the art. Such methods include, for example, radioimmunoassay (RIA), FACS, or PCR.
  • RIA radioimmunoassay
  • Normal or standard expression values of the IL-36 cytokine or IL-36R can be established by any suitable technique, e.g., by combining a sample comprising, or suspected of comprising, IL-36 cytokine or IL-36R with an IL-36 cytokine-specific or IL-36R-specific antibody under conditions suitable to form an antigen-antibody complex.
  • the antibody may be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, and radioactive materials (see, e.g., Zola , Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. (1987)).
  • Acne can be classified as mild, moderate, or severe by any accepted evaluation method.
  • the acne is moderate acne.
  • the acne is severe acne.
  • the subject will have acne characterized by (a) a facial Investigators Global Assessment (IGA) score of at least 3 (moderate), (b) at least about 20 inflammatory lesions on face (e.g., about 20 to about 50 inflammatory lesions), and/or (c) at least 20 non- inflammatory lesions on face (e.g., about 20 to about 100 non-inflammatory lesions).
  • IGA facial Investigators Global Assessment
  • the acne is characterized by the presense of no more than two nodules with a diameter greater than 5 mm; in other embodiments, the acne is characterized by the presence of more than two nodules with a diameter greater than 5 mm.
  • acne assessment methods and tools that take into account various factors, such as type of acne, severity of acne, number of acne lesions, anatomic location/extent of acne, quality of life and other psychosocial metrics, and scarring, among other measures.
  • the subject has acne classified as moderate or severe according to any of these assessement methods.
  • Potential assessment tools include the Investigator Global Assessment (IGA), the comprehensive acne severity scale (CASS) as described in Tan et al, J. Cutan. Med.
  • the subject has acne classified as moderate or severe according to any of these assessement methods.
  • the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect.
  • the treatment reduces the severity or slows the onet or progression of one or more adverse symptoms of acne by any manner or degree, including, but not limited to, a reduction in the number, frequency, onset, recurrence or severity of acne lesisons (e.g., comedones, papules, pustules and/or nodules).
  • Reduction in adverse symptoms can be determined by any suitable technique, such as by any of the aforementioned assessment tools and methods.
  • IL-36 signaling can be inhibited by any suitable method, such as by administering an
  • IL-36 pathway inhibitor that inhibits or neutralizes the IL-36 pathway, e.g., at the level of the cytokines (i.e., inhibits or neutralizes the biological activity of IL-36a, IL-36P, or IL-36y), the receptor (i.e., inhibits or neutralizes the biological activity of IL-36R), or inhibits or neutralizes the subsequent intracellular signaling induced by the IL-36 cytokines or IL-36R.
  • Any IL-36 pathway inhibitor can be used, provided the inhibitor has an effect that is sufficiently rapid and persistent to allow for a therapeutic effect within the dosing parameters described herein.
  • the method can include, for instance, administering to a subject in need thereof an agent that specifically binds to IL-36R; an agent that specifically binds to an IL-36 cytokine (e.g., IL-36a, IL-36P, or IL-36y); or a combination thereof.
  • an agent that specifically binds to IL-36R e.g., IL-36a, IL-36P, or IL-36y
  • an agent that specifically binds to an IL-36 cytokine e.g., IL-36a, IL-36P, or IL-36y
  • IL-36 pathway inhibitors including antibodies or antigen binding fragments thereof that bind to an IL-36 cytokine (e.g., IL-36a, IL-36P, or IL-36y) or IL-36R, several of which are known in the art including sepsolimab (Boehringer Ingleheim), ANB-019 (AnaptysBio, Inc.), and any of the compounds and compositions disclosed in WO2016168542A1; WO 2020018503 A2;
  • the IL-36 pathway inhibitor is an IL-36R binding agent, such as an antibody or antigen-binding antibody fragment, comprising an immunoglobulin heavy chain polypeptide (or at least variable region thereof) and an immunoglobulin light chain polypeptide (or at least variable region thereof).
  • the IL-36R binding agent can be, for example, any binding agent described in WO2016168542A1.
  • a whole immunoglobulin typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide.
  • Each of the heavy chains contains one N-terminal variable (VH) region and three C-terminal constant (CHI, CH2, and CH3) regions, and each light chain contains one N-terminal variable (VL) region and one C-terminal constant (CL) region.
  • the light chains of antibodies can be assigned to one of two distinct types, either kappa (K) or lambda (l), based upon the amino acid sequences of their constant domains.
  • each light chain is linked to a heavy chain by disulfide bonds, and the two heavy chains are linked to each other by disulfide bonds.
  • the light chain variable region is aligned with the variable region of the heavy chain
  • the light chain constant region is aligned with the first constant region of the heavy chain.
  • the remaining constant regions of the heavy chains are aligned with each other.
  • an immunoglobulin heavy chain or light chain “polypeptide” is used to refer to a whole immunoglobulin polypeptide or a portion or region thereof (e.g., a variable region).
  • variable regions of each pair of light and heavy chains form the antigen binding site of an antibody.
  • the VH and VL regions have the same general structure, with each region comprising four framework (FW or FR) regions.
  • framework region refers to the relatively conserved amino acid sequences within the variable region which are located between the hypervariable or complementary determining regions (CDRs).
  • CDRs hypervariable or complementary determining regions
  • the framework regions form the b sheets that provide the structural framework of the variable region (see, e.g., C.A. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001)).
  • the framework regions are connected by three complementarity determining regions (CDRs).
  • CDR1, CDR2, and CDR3 form the “hypervariable region” of an antibody, which is responsible for antigen binding.
  • the CDR regions also can be referred to using an ⁇ ” or “L” in the nomenclature to denote the heavy or light chain, respectively, i.e., CDRH1, CDRH2, CDRH3, CDRLl, CDRL2, or CDRL3.
  • the CDRs of a given Ig sequence can be determined by any of several conventional numbering schemes, such as Rabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo (see, e.g., Rabat, et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, NIH (1991); Chothia, et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol., 196:901-917 (1987); Al-Lazikani et al., Standard Conformations for the Canonical Structures of Immunoglobulins, J. Mol.
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of the amino acid sequence of Gin Val Gin Xaal Xaa2 Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr Asp lie Asn Trp Val Arg Gin Ala Pro Gly Gin Xaa3 Leu Glu Trp Met Gly Trp lie Tyr Pro Gly Asp Xaa4 Ser Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr He Thr Xaa5 Asp Xaa6 Ser Ala Xaa7 Thr Ala Tyr Met Glu Leu Xaa8 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Xaa9 Cys Thr Arg Ser Phe Tyr Thr Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ser (SEQ ID NO:
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of the amino acid sequence Gin Val Gin Xaal Xaa2 Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Ser Tyr Asp lie Asn Trp Val Arg Gin Ala Pro Gly Gin Xaa3 Leu Glu Trp Met Gly Trp lie Tyr Pro Gly Asp Xaa4 Ser Thr Lys Tyr Asn Glu Lys Phe Lys Gly Arg Val Thr He Thr Xaa5 Asp Xaa6 Ser Ala Ser Thr Ala Tyr Met Glu Leu Xaa7 Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Xaa8 Cys Thr Arg Ser Phe Tyr Thr Met Asp Tyr Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser Ser (SEQ ID NO: 1), or at least the CDR
  • the heavy chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 1, or at least the CDRs thereof, with any one of the aforementioned amino acid substitutions in any suitable combination.
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of an amino acid sequence of any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14, or at least the CDRs thereof.
  • the IL-36R binding agent comprises: a CDR1 of the heavy chain variable region (HCDR1) comprising, consisting of, or consisting essentially of the amino acid sequence Phe Thr Phe Thr Ser Tyr Asp He Asn (SEQ ID NO: 59); a CDR2 of the heavy chain variable region (HCDR2) comprising, consisting of, or consisting essentially of the amino acid sequence of (a) Trp He Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys Phe Lys Gly (SEQ ID NO: 60); (b) Trp He Tyr Pro Gly Asp Ser Ser Thr Lys Tyr Asn Glu Lys Phe Lys Gly (SEQ ID NO: 61); or (c) Trp He Tyr Pro Gly Asp Ala Ser Thr Lys Tyr Asn Glu Lys Phe Lys Gly (SEQ ID NO: 62); and/or a CDR3 of the heavy chain variable region (HCDR3) comprising, consisting of, consisting of,
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of the amino acid sequence Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Xaal Met Xaa2 Trp Val Arg Gin Ala Pro Xaa3 Gin Gly Leu Glu Trp Met Gly Met Phe Xaa4 Pro Xaa5 Xaa6 Xaa7 Val Thr Arg Leu Asn Gin Lys Phe Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Met lie lie Gly Gly Phe Ala Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser (SEQ ID NO: 15), or at
  • the heavy chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 15, or at least the CDRs thereof, with one of the aforementioned amino acid substitutions in any suitable combination.
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of an ammo acid sequence of any one of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24, or at least the CDRs thereof.
  • the IL-36R binding agent comprises a heavy chain variable region comprising: an HCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Tyr Thr Phe Thr Asn Tyr Trp Met His (SEQ ID NO: 64); (b) Tyr Thr Phe Thr Asn Tyr Trp Met Asn (SEQ ID NO: 65); (c) Tyr Thr Phe Thr Asn Tyr Trp Met Tyr (SEQ ID NO: 66); and (d) Tyr Thr Phe Thr Asn Tyr Tyr Met Asn (SEQ ID NO: 67); an HCDR2 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Met Phe Asp Pro Ser Asn Ser Val Thr Arg Leu Asn Gin Lys Phe Lys Asp (SEQ ID NO: 68); (b) Met Phe Glu Pro Ser Asn Ala Val Thr Arg Leu Asn Gin Lys Phe Lys Asp (S
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of the amino acid sequence of Xaal Xaa2 Gin Xaa3 Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin Thr Leu Ser Leu Thr Cys Thr Val Xaa4 Xaa5 Tyr Ser He Thr Xaa6 Asp Phe Ala Trp Asn Trp He Arg Gin Xaa7 Pro Gly Xaa8 Xaa9 Leu Glu Trp He Gly Tyr He Ser Tyr Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr He XaalO Xaal 1 Asp Thr Ser Lys Asn Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Xaal2 Tyr Xaal 3 Cys Ala He Arg Gly Pro Tyr Ser Phe Thr Tyr Trp Gly Gin Gly Thr Thr
  • the heavy chain variable region comprises, consists of, or consists essentially of the amino acid sequence Xaal Val Gin Xaa2 Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin Thr Leu Ser Leu Thr Cys Thr Val Xaa3 Gly Tyr Ser He Thr Ser Asp Phe Ala Trp Asn Trp He Arg Gin Xaa4 Pro Gly Xaa5 Xaa6 Leu Glu Trp He Gly Tyr He Ser Tyr Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr He Xaa7 Xaa8 Asp Thr Ser Lys Asn Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Xaa9 Cys Ala He Arg Gly Pro Tyr Ser Phe Thr Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser (SEQ ID NO: 25), or at least the CDRs thereof,
  • the heavy chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 57 or SEQ ID NO: 25, or at least the CDRs thereof, with one or more of the aforementioned amino acid substitutions in any suitable combination.
  • the immunoglobulin heavy chain variable region comprises, consists of, or consists essentially of an amino acid sequence of any one of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, or SEQ ID NO: 54, or at least the CDRs thereof.
  • the IL-36R binding agent may comprise an HCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Tyr Ser lie Thr Ser Asp Phe Ala Trp Asn (SEQ ID NO: 73); and (b) Tyr Ser lie Thr Ala Asp Phe Ala Trp Asn (SEQ ID NO: 74); an HCDR2 comprising, consisting of, or consisting essentially of the amino acid sequence Tyr He Ser Tyr Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Lys Ser (SEQ ID NO: 75); and/or an HCDR3 comprising, consisting of, or consisting essentially of the amino acid sequence Arg Gly Pro Tyr Ser Phe Thr Tyr (SEQ ID NO: 76).
  • an HCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Tyr Ser lie Thr Ser Asp Phe Ala Trp Asn (SEQ ID NO: 73
  • the IL-36R binding agent comprises an immunoglobulin heavy chain variable region which comprises, consists of, or consists essentially of the amino acid sequence of SEQ ID NO: 33, SEQ ID NO: 34, or SEQ ID NO: 35, or at least the CDRs thereof.
  • the immunoglobulin heavy chain variable region comprises an amino acid sequence that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to any of the foregoing variable region sequences.
  • Nucleic acid or amino acid sequence “identity,” as described herein, can be determined by comparing a nucleic acid or amino acid sequence of interest to a reference nucleic acid or amino acid sequence.
  • the percent identity is the number of nucleotides or amino acid residues that are the same (i.e., that are identical) as between the sequence of interest and the reference sequence divided by the length of the longest sequence (i.e., the length of either the sequence of interest or the reference sequence, whichever is longer).
  • a number of mathematical algorithms for obtaining the optimal alignment and calculating identity between two or more sequences are known and incorporated into a number of available software programs.
  • Such programs include CLUSTAL-W, T- Coffee, and ALIGN (for alignment of nucleic acid and amino acid sequences), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and later versions thereof) and LASTA programs (e.g., LASTA3x, LASTM, and SSEARCH) (for sequence alignment and sequence similarity searches).
  • BLAST programs e.g., BLAST 2.1, BL2SEQ, and later versions thereof
  • LASTA programs e.g., LASTA3x, LASTM, and SSEARCH
  • Sequence alignment algorithms also are disclosed in, for example, Altschul et al, J. Molecular Biol., 215(3): 403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci.
  • the IL-36R binding agent comprises an immunoglobulin light chain variable region that comprises, consists of, or consists essentially of the amino acid sequence Asp lie Val Met Thr Gin Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser lie Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Xaal Asn Thr Tyr Leu Tyr Trp Xaa2 Leu Gin Lys Pro Gly Gin Ser Pro Gin Leu Leu He Xaa3 Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys He Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Tyr Cys Met Gin His Leu Glu Tyr Pro Phe Thr Phe Gly Gin Gly Thr Lys Leu Glu He Lys (SEQ ID NO: 36), or at least the CDRs thereof, wherein (SEQ ID NO: 36), or at least the CDRs thereof,
  • the light chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 36, or at least the CDRs thereof, with one or more of the aforementioned amino acid substitutions in any suitable combination.
  • the isolated immunoglobulin light chain variable region comprises, consists of, or consists essentially of an amino acid sequence of any one of SEQ ID NO: 37, SEQ ID NO: 38, or SEQ ID NO: 39, or at least the CDRs thereof.
  • the IL-36R binding agent comprises a CDR1 of the light chain variable region (LCDR1) comprising, consisting of, or consisting essentially of the amino acid sequence selected of (a) Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr (SEQ ID NO: 77); or (b) Arg Ser Ser Lys Ser Leu Leu His Ser Asn Ala Asn Thr Tyr Leu Tyr (SEQ ID NO: 78); a CDR2 of the light chain variable region (LCDR2) comprising, consisting of, or consisting essentially of the amino acid sequence Arg Met Ser Asn Leu Ala Ser (SEQ ID NO: 79); and a CDR3 of the light chain variable region (LCDR3) comprising, consisting of, or consisting essentially of the amino acid sequence Met Gin His Leu Glu Tyr Pro Phe Thr (SEQ ID NO: 80).
  • LCDR1 of the light chain variable region LCDR1 comprising, consisting of, or consisting essentially of the
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of the amino acid sequence Asp lie Val Met Thr Gin Thr Pro Leu Ser Leu Ser Val Thr Pro Gly Gin Pro Ala Ser lie Ser Cys Arg Ser Ser Lys Ser Leu Leu His Xaal Asn Xaa2 He Thr Tyr Phe Tyr Trp Tyr Leu Xaa3 Lys Pro Gly Gin Pro Pro Gin Leu Leu He Tyr Gin Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys He Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Tyr Cys Ala Gin Asn Leu Glu Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu He Lys (SEQ ID NO: 40), or at least the CDRs thereof, wherein (a) Xaal is serine (Ser) or arginine
  • the light chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 40, or at least the CDRs thereof, with the aforementioned amino acid substitutions in any combination.
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of an amino acid sequence of any one of SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, or SEQ ID NO: 44; or at least hte CDRs thereof.
  • the light chain variable region comprises a LCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence (a) Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly He Thr Tyr Phe Tyr (SEQ ID NO: 81); (b) Arg Ser Ser Lys Ser Leu Leu His Ser Asn Ala He Thr Tyr Phe Tyr (SEQ ID NO: 82); or (c) Arg Ser Ser Lys Ser Leu Leu His Arg Asn Ala He Thr Tyr Phe Tyr (SEQ ID NO: 83); a LCDR2 comprising, consisting of, or consisting essentially of the amino acid sequence Gin Met Ser Asn Leu Ala Ser (SEQ ID NO: 84); and a LCDR3 comprising, consisting of, or consisting essentially of the amino acid sequence Ala Gin Asn Leu Glu Leu Pro Leu Thr (SEQ ID NO: 85).
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of the amino acid sequence of Asp lie Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr lie Thr Cys Arg Ala Ser Gin Xaal He Asn Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He Tyr Tyr Thr Ser Xaa2 Leu His Ser Gly Val Pro Ser Arg Phe Ser Xaa3 Ser Gly Ser Gly Xaa4 Asp Xaa5 Thr Phe Thr He Ser Ser Leu Gin Pro Glu Asp He Ala Thr Tyr Tyr Cys Gin Gin Gly His Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu He Lys Xaa6 Xaa7 (SEQ ID NO: 58), or at least the CDRs thereof, wherein (a) Xaal is aspart
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of the amino acid sequence Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Asn Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu He Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Xaal Ser Gly Ser Gly Thr Asp Xaa2 Thr Phe Thr He Ser Ser Leu Gin Pro Glu Asp He Ala Thr Tyr Tyr Cys Gin Gin Gly His Thr Leu Pro Trp Thr Phe Gly Gly Gly Gly Thr Lys Val Glu He Lys (SEQ ID NO: 45), or at least the CDRs thereof, wherein (a) Xaal is serine (Ser) or proline (Pro), and (b) Xaa2 is phenylalan
  • the light chain variable region can comprise, consist of, or consist essentially of the amino acid sequence of SEQ ID NO: 58 or SEQ ID NO: 45, or at least the CDRs thereof, with one or more of the aforementioned amino acid substitutions in any suitable combination.
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of an amino acid sequence of any one of SEQ ID NO: 46, SEQ ID NO: 47, or SEQ ID NO: 55, or at least the CDRs thereof.
  • the light chain variable region comprises an LCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence (a) Arg Ala Ser Gin Asp He Asn Asn Tyr Leu Asn (SEQ ID NO: 86); or (b) Arg Ala Ser Gin Trp He Asn Asn Tyr Leu Asn (SEQ ID NO: 87); an LCDR2 comprising, consisting of, or consisting essentially of an amino acid sequence (a) Tyr Thr Ser Arg Leu His Ser (SEQ ID NO: 88); or (b) Tyr Thr Ser Met Leu His Ser (SEQ ID NO: 89); and an LCDR3 comprising, consisting of, or consisting essentially of the amino acid sequence Gin Gin Gly His Thr Leu Pro Trp Thr (SEQ ID NO: 90).
  • the immunoglobulin light chain variable region comprises, consists of, or consists essentially of the amino acid sequence of SEQ ID NO: 48,
  • SEQ ID NO: 49 or SEQ ID NO: 50, or at least the CDRs thereof.
  • the immunoglobulin light chain variable region comprises an amino acid sequence that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to any of the foregoing immunoglobulin light chain variable region sequences.
  • Nucleic acid or amino acid sequence “identity” can be determined using the methods described herein.
  • the IL-36R binding agent can comprise an immunoglobulin heavy chain variable region and light chain variable region have any of the foregoing heavy and light chain variable region sequences, or the CDRs thereof.
  • the CDR sequences can be the CDR sequences set forth herein or the CDR sequences as determined using any of several known methods (e.g., Rabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo).
  • the IL-36R binding agent has an immunoglobulin heavy chain variable region comprising SEQ ID NO: 15 or SEQ ID NO: 22, or at least the CDR regions thereof; and an immunoglobulin light chain variable region comprising SEQ ID NO: 40 or SEQ ID NO: 44, or at least the CDR sequences thereof, wherein the CDRs are as determined with determined in accordance with any of the various known immunoglobulin numbering schemes, particularly in accordance with Rabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo.
  • the antibody comprises a heavy chain variable region of SEQ ID NO: 22 and light chain variable region of SEQ ID NO: 44, or at least the CDRs thereof as determined by Rabat.
  • the antibody comprises a heavy chain variable region of SEQ ID NO: 22 and light chain variable region of SEQ ID NO: 44, or at least the CDRs thereof as determined by Chothia. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 22 and light chain variable region of SEQ ID NO: 44, or at least the CDRs thereof as determined by Martin. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 22 and light chain variable region of SEQ ID NO: 44, or at least the CDRs thereof as determined by IGMT. In some embodiments, the antibody comprises a heavy chain variable region of SEQ ID NO: 22 and light chain variable region of SEQ ID NO: 44, or at least the CDRs thereof as determined by AHo.
  • the IL-36R binding agent comprises a heavy chain variable region comprising: an HCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Tyr Thr Phe Thr Asn Tyr Trp Met His (SEQ ID NO: 64); (b) Tyr Thr Phe Thr Asn Tyr Trp Met Asn (SEQ ID NO: 65); (c) Tyr Thr Phe Thr Asn Tyr Trp Met Tyr (SEQ ID NO: 66); and (d) Tyr Thr Phe Thr Asn Tyr Tyr Met Asn (SEQ ID NO: 67); an HCDR2 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of (a) Met Phe Asp Pro Ser Asn Ser Val Thr Arg Leu Asn Gin Lys Phe Lys Asp (SEQ ID NO: 68); (b) Met Phe Glu Pro Ser Asn Ala Val Thr Arg Leu Asn Gin Lys
  • the IL-36R binding agent comprises a heavy chain variable region comprising: an HCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of Tyr Thr Phe Thr Asn Tyr Trp Met Asn (SEQ ID NO: 65); an HCDR2 comprising, consisting of, or consisting essentially of the amino acid sequence selected from the group consisting of Met Phe His Pro Thr Gly Asp Val Thr Arg Leu Asn Gin Lys Phe Lys Asp (SEQ ID NO: 71); and/or an HCDR3 comprising, consisting of, or consisting essentially of the amino acid sequence Thr Thr Ser Met He He Gly Gly Phe Ala Tyr (SEQ ID NO: 72); and comprises a light chain variable region comprising a LCDR1 comprising, consisting of, or consisting essentially of the amino acid sequence Arg Ser Ser Lys Ser Leu Leu His Arg Asn Ala lie Thr Tyr Phe Tyr (
  • the IL-36R binding agent can comprise an immunoglobulin heavy chain variable region and light chain variable region having specified percent identities to the heavy and light chain variable region sequences, such as at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical).
  • the variance in sequence occurs outside the CDRs (as determined by any known method including Rabat, Chothia, Martin (Enhanced Chothia), IGMT, or AHo), such that the heavy and light chain sequences having the specified sequence identity to the specific sequences set forth herein retain the CDRs of such sequences.
  • the IL-36R binding agent comprises an immunoglobulin heavy chain variable region that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to SEQ ID NO: 15 or SEQ ID NO: 22, optionally wherein the sequence retains the CDRs of SEQ ID NO: 15 or SEQ ID NO: 22; and comprises an immunoglobulin heavy chain variable region that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to SEQ ID NO: 40 or SEQ ID NO: 44, optionally wherein the sequence retains the CDRs of SEQ ID NO: 40 or SEQ ID NO: 44; wherein the CDRs are as determined in accordance with any of the various
  • the IL-36R binding agent comprises an immunoglobulin heavy chain variable region that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to SEQ ID NO: 22, optionally wherein the sequence retains the CDRs of SEQ ID NO: 22; and comprises an immunoglobulin heavy chain variable region that is at least 90% identical (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to SEQ ID NO: 44, optionally wherein the sequence retains the CDRs of SEQ ID NO: 44; wherein the CDRs are as determined in accordance with any of the various known immunoglobulin numbering schemes, particularly in accordance with Rabat, Chothia, Martin (Enhanced Chothi
  • Variation in sequence identity can be accomplished through addition, substitution, or deletion of one or more amino acid residues.
  • An amino acid “replacement” or “substitution” refers to the replacement of one amino acid at a given position or residue by another amino acid at the same position or residue within a polypeptide sequence.
  • the amino acid replacement or substitution can be conservative, semi-conservative, or non-conservative depending upon whether the substitution is by an amino acid residue that has similar properties to the residue being replaced.
  • a functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer- Verlag, New York (1979)). According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz and Schirmer, supra).
  • Amino acids can be broadly grouped as “aromatic” or “aliphatic.”
  • An aromatic amino acid includes an aromatic ring.
  • aromatic amino acids include histidine (H or His), phenylalanine (F or Phe), tyrosine (Y or Tyr), and tryptophan (W or Trp).
  • Non-aromatic amino acids are broadly grouped as “aliphatic.”
  • “aliphatic” amino acids include glycine (G or Gly), alanine (A or Ala), valine (V or Val), leucine (L or Leu), isoleucine (I or lie), methionine (M or Met), serine (S or Ser), threonine (T or Thr), cysteine (C or Cys), proline (P or Pro), glutamic acid (E or Glu), aspartic acid (A or Asp), asparagine (N or Asn), glutamine (Q or Gin), lysine (K or Lys), and arginine (R or Arg).
  • Aliphatic amino acids may be sub-divided into four sub-groups.
  • the “large aliphatic non-polar sub-group” consists of valine, leucine, and isoleucine.
  • the “aliphatic slightly-polar sub-group” consists of methionine, serine, threonine, and cysteine.
  • the “aliphatic polar/charged sub-group” consists of glutamic acid, aspartic acid, asparagine, glutamine, lysine, and arginine.
  • the “small-residue sub-group” consists of glycine and alanine.
  • the group of charged/polar amino acids may be sub-divided into three sub-groups: the “positively-charged sub-group” consisting of lysine and arginine, the “negatively-charged sub-group” consisting of glutamic acid and aspartic acid, and the “polar sub-group” consisting of asparagine and glutamine.
  • Aromatic amino acids may be sub-divided into two sub-groups: the “nitrogen ring sub-group” consisting of histidine and tryptophan and the “phenyl sub-group” consisting of phenylalanine and tyrosine.
  • conservative amino acid substitutions include substitutions of amino acids within the sub-groups described above, for example, lysine for arginine and vice versa such that a positive charge may be maintained, glutamic acid for aspartic acid and vice versa such that a negative charge may be maintained, serine for threonine such that a free -OH can be maintained, and glutamine for asparagine such that a free -NH2 can be maintained.
  • “Semi conservative mutations” include amino acid substitutions of amino acids within the same groups listed herein, but not within the same sub-group. For example, the substitution of aspartic acid for asparagine, or asparagine for lysine, involves amino acids within the same group, but different sub-groups.
  • “Non-conservative mutations” involve amino acid substitutions between different groups, for example, lysine for tryptophan, or phenylalanine for serine, etc.
  • the immunoglobulin light chain or heavy chain variable region “consists essentially of’ any of the foregoing heavy or light chain variable region amino acid sequences additional components can be included in the polypeptide that do not materially affect the polypeptide, such as those described herein.
  • the immunoglobulin light chain or heavy chain variable region “consists of’ the polypeptide does not comprise any additional components.
  • the IL-36R binding agent (e.g., antibody or antibody fragment) also can be a binding agent that competes with (e.g., binds to the same epitope or an overlapping epitope) an IL-36R binding agent comprising an immunoglobulin heavy chain variable region or light chain variable region described herein for binding to IL-36R (e.g., a binding agent comprising an Ig heavy chain comprising SEQ ID NO: 22 and an Ig light chain of SEQ ID NO: 44).
  • Antibody competition can be assayed using routine peptide competition assays which utilize ELISA, Western blot, or immunohistochemistry methods (see, e.g., U.S. Patents 4,828,981 and 8,568,992; and Braitbard et al., Proteome Sci., 4 ⁇ 12 (2006)).
  • the IL-36R-binding agent can have any suitable affinity to IL-36R or an epitope thereof.
  • affinity refers to the equilibrium constant for the reversible binding of two agents and is expressed as the dissociation constant (KD).
  • KD dissociation constant
  • Affinity of a binding agent to a ligand, such as affinity of an antibody for an epitope can be, for example, from about 1 picomolar (pM) to about 100 micromolar (mM) (e.g., from about 1 picomolar (pM) to about 1 nanomolar (nM), from about 1 nM to about 1 micromolar (mM), or from about 1 mM to about 100 mM).
  • the IL-36R-binding agent can bind to human IL-36R protein with a KD less than or equal to 1 nanomolar (e.g., 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.025 nM, 0.01 nM, 0.001 nM, or a range defined by any two of the foregoing values).
  • 1 nanomolar e.g., 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.025 nM, 0.01 nM, 0.001 nM, or a range defined by any two of the foregoing values).
  • the IL-36R-binding agent can bind to human IL-36R with a KD less than or equal to 200 pM (e.g., 190 pM, 175 pM, 150 pM, 125 pM, 110 pM, 100 pM, 90 pM, 80 pM, 75 pM, 60 pM, 50 pM, 40 pM, 30 pM, 25 pM, 20 pM, 15 pM, 10 pM, 5 pM, 1 pM, or a range defined by any two of the foregoing values).
  • 200 pM e.g., 190 pM, 175 pM, 150 pM, 125 pM, 110 pM, 100 pM, 90 pM, 80 pM, 75 pM, 60 pM, 50 pM, 40 pM, 30 pM, 25 pM, 20 pM, 15 pM, 10 pM, 5
  • the IL-36R binding agent cross-reacts with and inhibits both human and non-human primate (e.g., cynomolgus) IL- 36R.
  • Immunoglobulin affinity for an antigen or epitope of interest can be measured using any art-recognized assay. Such methods include, for example, fluorescence activated cell sorting (FACS), separable beads (e.g., magnetic beads), surface plasmon resonance (SPR), solution phase competition (KINEXATM), antigen panning, competitive binding assays, and/or ELISA (see, e.g., Janeway et al. (eds.), Immunobiology, 5th ed., Garland Publishing, New York, NY, 2001).
  • the IL-36R binding agent should have suitable stability in vivo.
  • the IL-36R-binding agent e.g., an antibody
  • has an in vivo half-life between about 30 minutes and 45 days e.g., about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 10 hours, about 12 hours, about 1 day, about 5 days, about 10 days, about 15 days, about 25 days, about 35 days, about 40 days, about 45 days, or a range defined by any two of the foregoing values).
  • the IL-36R-binding agent has an in vivo half-life between about 2 hours and 20 days (e.g., about 5 hours, about 10 hours, about 15 hours, about 20 hours, about 2 days, about 3 days, about 7 days, about 12 days, about 14 days, about 17 days, about 19 days, or a range defined by any two of the foregoing values).
  • the IL-36R-binding agent has an in vivo half-life between about 10 days and about 40 days (e.g., about 10 days, about 13 days, about 16 days, about 18 days, about 20 days, about 23 days, about 26 days, about 29 days, about 30 days, about 33 days, about 37 days, about 38 days, about 39 days, about 40 days, or a range defined by any two of the foregoing values).
  • the stability of the IL-36R-binding agent described herein also can be measured in terms of the transition mid-point value (T m ), which is the temperature where 50% of the amino acid sequence is in its native confirmation, and the other 50% is denatured.
  • T m transition mid-point value
  • the IL-36R- binding agent comprises a transition mid-point value (T m ) in vitro of about 60-100 °C.
  • the IL-36R-binding agent can comprise a T m in vitro of about 65-80 °C (e.g., 66 °C, 68 °C, 70 °C, 71 °C, 75 °C, or 79 °C), about 80-90 °C (e.g., about 81 °C, 85 °C, or 89 °C), or about 90-100 °C (e.g., about 91 °C, about 95 °C, or about 99 °C).
  • T m in vitro of about 65-80 °C (e.g., 66 °C, 68 °C, 70 °C, 71 °C, 75 °C, or 79 °C), about 80-90 °C (e.g., about 81 °C, 85 °C, or 89 °C), or about 90-100 °C (e.g., about 91 °C, about 95 °C, or about 99
  • the stability of the IL-36R-binding agent can be measured using any other suitable assay known in the art, such as, for example, measuring serum half-life, differential scanning calorimetry (DSC), thermal shift assays, and pulse-chase assays.
  • DSC differential scanning calorimetry
  • Other methods of measuring protein stability in vivo and in vitro that can be used in the context of the invention are described in, for example, Protein Stability and Folding, B. A. Shirley (ed.), Human Press, Totowa, New Jersey (1995); Protein Structure, Stability, and Interactions (Methods in Molecular Biology) , Shiver J.W. (ed.), Humana Press, New York, NY (2010); and Ignatova, Microb. Cell Fact., 4 23 (2005).
  • the IL-36R-binding agent desirably exhibits one or more of the following biological activities: (a) inhibits the interaction between IL-36R and IL-36a, IL-36P, and/or IL-36y, (b) inhibits intracellular signaling mediated by IL-36R, and/or (c) cross-reacts with and inhibits the activity of human and non-human primate (e.g., cynomolgus) IL-36R.
  • Other biological properties or characteristics of an antigen-binding agent recognized in the art include, for example, avidity, selectivity, solubility, folding, immunotoxicity, expression, and formulation.
  • the aforementioned properties or characteristics can be observed, measured, and/or assessed using standard techniques including, but not limited to, ELISA, competitive ELISA, surface plasmon resonance analysis (BIACORETM), or KINEXATM, in vitro or in vivo neutralization assays, receptor-ligand binding assays, cytokine or growth factor production and/or secretion assays, and signal transduction and immunohistochemistry assays.
  • standard techniques including, but not limited to, ELISA, competitive ELISA, surface plasmon resonance analysis (BIACORETM), or KINEXATM, in vitro or in vivo neutralization assays, receptor-ligand binding assays, cytokine or growth factor production and/or secretion assays, and signal transduction and immunohistochemistry assays.
  • inhibitor or “neutralize,” as used herein with respect to the activity of the IL-36 pathway inhibitor, e.g., the IL-36R-binding agent, refer to the ability to substantially antagonize, prohibit, prevent, restrain, slow, disrupt, alter, eliminate, stop, or reverse the progression or severity of, for example, the biological activity of an IL-36 cytokine or IL-36R, or a disease or condition associated with an IL-36 cytokine or IL-36R, e.g., acne.
  • the IL-36R-binding agent preferably inhibits or neutralizes the activity of IL-36R by at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 100%, or a range defined by any two of the foregoing values.
  • the IL-36R-binding agent of the present inventive method can be a whole antibody, as described herein, or an antibody fragment.
  • fragment of an antibody “antibody fragment,” and “functional fragment of an antibody” are used interchangeably herein to mean one or more fragments of an antibody that retain the ability to specifically bind to an antigen (see, generally, Holliger et al., Nat. Biotech., 23(9): 1126-1129 (2005)).
  • the IL-36R-binding agent can contain any IL-36R-binding antibody fragment.
  • the antibody fragment desirably comprises, for example, one or more CDRs, the variable region (or portions thereof), the constant region (or portions thereof), or combinations thereof.
  • antibody fragments include, but are not limited to, (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CHi domains, (ii) a F(ab’)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, (iii) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a Fab’ fragment, which results from breaking the disulfide bridge of an F(ab’)2 fragment using mild reducing conditions, (v) a disulfide-stabilized Fv fragment (dsFv), and (vi) a domain antibody (dAb), which is an antibody single variable region domain (VH or VH) polypeptide that specifically binds antigen.
  • a Fab fragment which is a monovalent fragment consisting of the VL, VH, CL, and CHi domains
  • the antibody or antibody fragment can comprise a heavy chain constant region (F c ) of any suitable class.
  • the antibody or antibody fragment comprises a heavy chain constant region that is based upon wild-type IgGl , IgG2, or IgG4 antibodies, or variants thereof. It will be appreciated that each antibody class, or isotype, engages a distinct set of effector mechanisms for disposing of or neutralizing antigen once recognized.
  • the IL-36R-binding agent when it is an antibody or antibody fragment, it can exhibit one or more effector functions, such as participation in antibody-dependent complement-mediated lysis or antibody- dependent cellular toxicity via interactions with effector molecules and cells (e.g., activation of the complement system).
  • effector functions such as participation in antibody-dependent complement-mediated lysis or antibody- dependent cellular toxicity via interactions with effector molecules and cells (e.g., activation of the complement system).
  • the IL-36R-binding agent also can be a single chain antibody fragment.
  • single chain antibody fragments include, but are not limited to, (i) a single chain Fv (scFv), which is a monovalent molecule consisting of the two domains of the Fv fragment (i.e., VL and VH) joined by a synthetic linker which enables the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al, Science, 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat.
  • scFv single chain Fv
  • a diabody which is a dimer of polypeptide chains, wherein each polypeptide chain comprises a VH connected to a VL by a peptide linker that is too short to allow pairing between the VH and VL on the same polypeptide chain, thereby driving the pairing between the complementary domains on different VH -VL polypeptide chains to generate a dimeric molecule having two functional antigen binding sites.
  • Antibody fragments are known in the art and are described in more detail in, e.g., U.S. Patent Application Publication 2009/0093024 Al.
  • the IF-36R-binding agent also can be an intrabody or fragment thereof.
  • An intrabody is an antibody which is expressed and which functions intracellularly. Intrabodies typically lack disulfide bonds and are capable of modulating the expression or activity of target genes through their specific binding activity. Intrabodies include single domain fragments such as isolated VH and VL domains and scFvs.
  • An intrabody can include sub-cellular trafficking signals attached to the N or C terminus of the intrabody to allow expression at high concentrations in the sub-cellular compartments where a target protein is located.
  • an intrabody Upon interaction with a target gene, an intrabody modulates target protein function and/or achieves phenotypic/functional knockout by mechanisms such as accelerating target protein degradation and sequestering the target protein in a non-physiological sub-cellular compartment.
  • Other mechanisms of intrabody-mediated gene inactivation can depend on the epitope to which the intrabody is directed, such as binding to the catalytic site on a target protein or to epitopes that are involved in protein-protein, protein-DNA, or protein-RNA interactions.
  • the IL-36R-binding agent also can be an antibody conjugate.
  • the IL- 36R-binding agent can be a conjugate of (1) an antibody, an alternative scaffold, or fragments thereof, and (2) a protein or non-protein moiety comprising the IL-36R-binding agent.
  • the IL-36R-binding agent can be all or part of an antibody conjugated to a peptide, a fluorescent molecule, or a chemotherapeutic agent.
  • the IL-36R-binding agent can be, or can be obtained from, a human antibody, a non human antibody, or a chimeric antibody.
  • a “chimeric” antibody is an antibody or fragment thereof comprising both human and non-human regions.
  • the IL-36R-binding agent is a humanized antibody.
  • a “humanized” antibody is a monoclonal antibody comprising a human antibody scaffold and at least one CDR obtained or derived from a non-human antibody.
  • Non human antibodies include antibodies isolated from any non-human animal, such as, for example, a rodent (e.g., a mouse or rat).
  • a humanized antibody can comprise, one, two, or three CDRs obtained or derived from a non-human antibody.
  • CDRH3 of the IL-36R-binding agent is obtained or derived from a mouse monoclonal antibody, while the remaining variable regions and constant region of the IL-36R-binding agent are obtained or derived from a human monoclonal antibody.
  • a human antibody, a non-human antibody, a chimeric antibody, or a humanized antibody can be obtained by any means, including via in vitro sources (e.g., a hybridoma or a cell line producing an antibody recombinantly) and in vivo sources (e.g., rodents).
  • in vitro sources e.g., a hybridoma or a cell line producing an antibody recombinantly
  • in vivo sources e.g., rodents.
  • a human antibody or a chimeric antibody can be generated using a transgenic animal (e.g., a mouse) wherein one or more endogenous immunoglobulin genes are replaced with one or more human immunoglobulin genes.
  • transgenic mice wherein endogenous antibody genes are effectively replaced with human antibody genes include, but are not limited to, the Medarex HUMAB- MOUSETM, the Kirin TC MOUSETM, and the Kyowa Kirin KM-MOUSETM (see, e.g., Lonberg, Nat. Biotechnol., 23(9): 1117-25 (2005), and Lonberg, Handb. Exp. Pharmacol., 18P. 69-97 (2008)).
  • a humanized antibody can be generated using any suitable method known in the art (see, e.g., An, Z. (ed.), Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley & Sons, Inc., Hoboken, New Jersey (2009)), including, e.g., grafting of non-human CDRs onto a human antibody scaffold (see, e.g., Kashmiri et al., Methods, 36( 1): 25-34 (2005); and Hou et al., J. Biochem., 144( ⁇ ): 115-120 (2008)).
  • a humanized antibody can be produced using the methods described in, e.g., U.S. Patent Application Publication 2011/0287485 Al.
  • a CDR e.g., CDR1, CDR2, or CDR3
  • a variable region of the immunoglobulin heavy chain variable region and/or the immunoglobulin light chain variable region described herein can be transplanted (i.e., grafted) into another molecule, such as an antibody or non-antibody polypeptide, using either protein chemistry or recombinant DNA technology.
  • the invention encompasses an IL-36R-binding agent comprising at least one CDR of an immunoglobulin heavy chain and/or light chain variable region as described herein.
  • the IL-36R-binding agent can comprise one, two, or three CDRs of an immunoglobulin heavy chain and/or light chain variable region as described herein.
  • the IL-36R binding agent can be formulated as a composition for administration to a subject (e.g., a mammal, such as a human or non- human primate) by any suitable route of administration, including oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration.
  • the composition preferably is suitable for parenteral administration.
  • parenteral includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration.
  • the composition is administered to a mammal using peripheral systemic delivery by intravenous or subcutaneous injection.
  • the composition can comprise the IL-36R binding agent and a suitable carrier such as are well known in the art.
  • a suitable carrier such as are well known in the art.
  • the choice of carrier will be determined, in part, by the particular site to which the composition may be administered and the particular method used to administer the composition.
  • the composition optionally can be sterile.
  • the composition can be frozen or lyophilized for storage and reconstituted in a suitable sterile carrier prior to use.
  • the compositions can be generated in accordance with conventional techniques described in, e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams &
  • Tthe IL-36R binding agent can be used at dosages and for periods of time necessary, to achieve a desired pharmacologic and/or physiologic effect (“therapeutically effective amount”).
  • the therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the IL-36 pathway inhibitor, e.g., the IL-36R-binding agent, to elicit a desired response in the individual.
  • a therapeutically effective amount of an inhibitor of the IL-36 pathway can an amount that decreases the bioactivity of any one of the IL-36 cytokines and/or IL-36R, and thus decreases the activity of the IL-36 signalling pathway.
  • the dose is in the range of 1 pg/kg to 20 mg/kg of animal or human body weight; however, doses below or above this exemplary range are within the scope of the invention.
  • the daily parenteral dose can be about 0.00001 pg/kg to about 20 mg/kg of total body weight (e.g., about 0.001 pg /kg, about 0.1 pg /kg , about 1 pg /kg, about 5 pg /kg, about 10 pg/kg, about 100 pg /kg, about 500 pg/kg, about 1 mg/kg, about 5 mg/kg, about 10 mg/kg, or a range defined by any two of the foregoing values), preferably from about 0.1 pg/kg to about 10 mg/kg of total body weight (e.g., about 0.5 pg/kg, about 1 pg/kg, about 50 pg/kg, about 150 pg/kg, about 300 pg/kg, about 750 pg//
  • the dose is about 20 mg or more (e.g., about 30 mg or more, about 50 mg or more, about 75 mg or more, or about 100 mg or more), and about 1000 mg or less (e.g., about 900 mg or less, about 800 mg or less, about 700 mg or less, about 600 mg or less, about 500 mg or less, about 400 mg or less, or about 300 mg or less) every 1-6 weeks (e.g., every week, every two weeks, every three weeks or every four weeks).
  • the IL-36 inhibitor is administered in a single loading does of about 1.5x-10x (e.g., about 2x-8x) the amount of following maintenance doses.
  • the IL-36R binding agent can be administered in a loading dose of about 200 mg-750 mg (e.g., about 300 mg -500 mg, or about 350 mg - 450 mg) followed by a maintenance dose of about 50-300 mg (e.g., about 100 mg - 300 mg or about 150 mg - 250 mg) every two weeks or every month or two months (e.g., every 2-8 weeks or 2-4 weeks) thereafter as needed to effect or maintain a therapeutic response.
  • a loading dose of about 200 mg-750 mg (e.g., about 300 mg -500 mg, or about 350 mg - 450 mg) followed by a maintenance dose of about 50-300 mg (e.g., about 100 mg - 300 mg or about 150 mg - 250 mg) every two weeks or every month or two months (e.g., every 2-8 weeks or 2-4 weeks) thereafter as needed to effect or maintain a therapeutic response.
  • the IL-36R binding agent provides a long-lasting effect against acne and allows for relatively infrequent dosing, for instance, on a schedule of not more than once every 14 days, 21 days, or 30 days. In some embodiments, an even longer interval can be used (e.g., not more than once every 45 days, 60 days, 90 days, or 120 days).
  • Therapeutic efficacy can be monitored by periodic assessment of treated patients. For repeated administrations over several days or longer, depending on the condition, the treatment can be repeated until a desired suppression of acne occurs, or alternatively, the treatment can be continued for the lifetime of the patient.
  • other dosage regimens may be useful and are within the scope of the invention.
  • the desired dosage can be delivered by a single bolus administration of the IL-36R binding agent or composition described herein, by multiple bolus administrations of the IL-36R binding agent composition described herein, or by continuous infusion administration of the IL-36R binding agent or composition described herein.
  • the IL-36R-binding agent of the invention may be administered alone or in combination with other drugs.
  • the IL-36R-binding agent can be administered in combination with other agents for the treatment or prevention of the diseases disclosed herein, such as an anti-inflammatory agent including, for example, corticosteroids (e.g., prednisone and fluticasone), non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen, and naproxen), biologies (e.g., infliximab (REMICADETM), adalimumab (HUMIRATM), or etanercept (ENBRELTM)), methotrexate (MTX), an oral retinoid (e.g. acitretin (SORIATANETM)), topical steroids, anti-infectives and/or antibiotics, or other agents useful for alleviating the severity of acne symptoms.
  • corticosteroids e.g., prednisone
  • the invention further encompasses an IL-36R binding agent or composition comprising same, as described herein, for use to treat acne in accordance with the methods provided herein.
  • the IL-36R binding agent comprises an immunoglobulin heavy chain variable region of SEQ ID NO: 22 or at least the CDRs thereof, and an immunoglobulin light chain variable region of SEQ ID NO: 44 or at least the CDRs thereof, as described herein.
  • IL-36a, IL-36P, IL-36y, and IL-36Ra was measured in samples from skin lesions of patients with moderate to severe acne, and the expression levels compared to the expression levels found in normal skin from healthy subjects. Expression levels of all four biomarkers were increased in the acne patients. In particular, IL-36 g expression levels were found to be more than ten-fold higher in the acne patient samples than in normal samples, and IL-36a and IL-36P levels in the acne patient samples were found to be more than 5-fold higher than in normal samples (data normalized to the housekeeping gene 18S).

Abstract

L'invention concerne des méthodes de traitement de l'acné chez un sujet avec un inhibiteur de la voie de l'interleukine-36 (IL-36), et des méthodes de sélection d'un sujet pour une thérapie avec l'inhibiteur de la voie de l'IL-36.
PCT/US2022/011700 2021-01-08 2022-01-07 Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r) WO2022150644A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135248P 2021-01-08 2021-01-08
US63/135,248 2021-01-08

Publications (1)

Publication Number Publication Date
WO2022150644A1 true WO2022150644A1 (fr) 2022-07-14

Family

ID=80122998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/011700 WO2022150644A1 (fr) 2021-01-08 2022-01-07 Thérapie contre l'acné par récepteur de l'interleukine 36 (il-36r)

Country Status (1)

Country Link
WO (1) WO2022150644A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US20090093024A1 (en) 2007-02-20 2009-04-09 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2013074569A1 (fr) 2011-11-16 2013-05-23 Boehringer Ingelheim International Gmbh Anticorps anti-il-36r
US8568992B2 (en) 2001-12-03 2013-10-29 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2016168542A1 (fr) 2015-04-15 2016-10-20 Anaptysbio, Inc. Anticorps dirigés contre le récepteur de l'interleukine 36 (il-36r)
WO2018183173A1 (fr) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Polythérapie à base d'anticorps anti il-36r
WO2019177883A2 (fr) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
WO2020018503A2 (fr) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anticorps anti-il36r
WO2020065594A1 (fr) * 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Anticorps il-36 et leurs utilisations
US20200199217A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
WO2021259880A1 (fr) * 2020-06-22 2021-12-30 Almirall, S.A. Anticorps anti-il-36 et leurs procédés d'utilisation

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US8568992B2 (en) 2001-12-03 2013-10-29 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20090093024A1 (en) 2007-02-20 2009-04-09 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US20110287485A1 (en) 2007-02-20 2011-11-24 Anaptysbio, Inc. Methods of generating libraries and uses thereof
US10550189B2 (en) 2011-11-16 2020-02-04 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
WO2013074569A1 (fr) 2011-11-16 2013-05-23 Boehringer Ingelheim International Gmbh Anticorps anti-il-36r
US9023995B2 (en) 2011-11-16 2015-05-05 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
WO2016168542A1 (fr) 2015-04-15 2016-10-20 Anaptysbio, Inc. Anticorps dirigés contre le récepteur de l'interleukine 36 (il-36r)
WO2018183173A1 (fr) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Polythérapie à base d'anticorps anti il-36r
WO2019177883A2 (fr) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Utilisation d'anticorps anti-il-36 r pour le traitement d'une maladie intestinale inflammatoire
WO2020018503A2 (fr) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anticorps anti-il36r
WO2020065594A1 (fr) * 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Anticorps il-36 et leurs utilisations
US20200199217A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
WO2021259880A1 (fr) * 2020-06-22 2021-12-30 Almirall, S.A. Anticorps anti-il-36 et leurs procédés d'utilisation

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, CSH PRESS
"Biological Sequence Analysis: Probabalistic Models of Proteins and Nucleic Acids", 2009, CAMBRIDGE UNIVERSITY PRESS
"Protein Stability and Folding", 1995, HUMAN PRESS
"Protein Structure, Stability, and Interactions", 2010, HUMANA PRESS
"Remington: The Science and Practice of Pharmacy", 2001, LIPPINCOTT WILLIAMS & WILKINS
ABHINANDAN ET AL.: "Analysis and Improvements to Kabat and Structurally Correct Numbering of Antibody Variable Domains", MOL. IMMUNOL., vol. 45, 2008, pages 3832 - 3839, XP023437109, DOI: 10.1016/j.molimm.2008.05.022
ALTSCHUL ET AL., J. MOLECULAR BIOL., vol. 215, no. 3, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402
ANONYMOUS: "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris", 23 April 2021 (2021-04-23), XP055899562, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04856917> [retrieved on 20220310] *
BEIGERT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 106, no. 10, 2009, pages 3770 - 3775
BHAMBRI ET AL., J. DRUGS IN DERM., vol. 8, no. 7, 2009, pages 61618
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BRAITBARD ET AL., PROTEOME SCI., vol. 4, 2006, pages 12
BURKE ET AL., BR. J. DERM., vol. 111, no. 1, 1984, pages 8883 - 92
CHOTHIA ET AL.: "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917, XP024010426, DOI: 10.1016/0022-2836(87)90412-8
DI CAPRIO ROBERTA ET AL: "IL-36 cytokines are increased in acne and hidradenitis suppurativa", ARCHIVES OF DERMATOLOGICAL RESEARCH, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 309, no. 8, 29 August 2017 (2017-08-29), pages 673 - 678, XP036324354, ISSN: 0340-3696, [retrieved on 20170829], DOI: 10.1007/S00403-017-1769-5 *
DINARELLO ET AL., NAT. IMMUNOL., vol. 11, no. 11, pages 973
DOSHI ET AL., INT'L J. DERM., vol. 36, 1997, pages 416 - 418
DRENO ET AL., DERMATOLOGY, vol. 214, 2007, pages 46 - 51
DRENO ET AL., J. EUR. ACAD. DERMATOL. VENEREOL., vol. 25, no. 1, 2011, pages 43 - 48
EL-ESAWY F.M. ET AL: "Evaluating the Role of Interleukin-36 and Interleukin-38 in Acne Vulgaris Patients", BENHA JOURNAL OF APPLIED SCIENCES, vol. 5, no. 7, 1 October 2020 (2020-10-01), pages 1 - 6, XP055899756, DOI: 10.21608/bjas.2020.137315 *
GUPTA ET AL., ACTA DERM VENEREOL (STOCKH, vol. 78, 1998, pages 451 - 456
GUSFIELD: "Algorithms on Strings, Trees and Sequences", 1997, CAMBRIDGE UNIVERSITY PRESS
HOLLIGER ET AL., NAT. BIOTECH., vol. 23, no. 9, 2005, pages 1126 - 1129
HONEGGER ET AL.: "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J. MOL. BIOL., vol. 309, 2001, pages 657 - 670, XP004626893, DOI: 10.1006/jmbi.2001.4662
HOU ET AL., BIOCHEM., vol. 144, no. 1, 2008, pages 115 - 120
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
IGNATOVA, MICROB. CELL FACT., vol. 4, 2005, pages 23
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KASHMIRI ET AL., METHODS, vol. 36, no. 1, 2005, pages 25 - 34
KOHLERMILSTEIN, EUR. J. IMMUNOL., vol. 5, 1976, pages 511 - 519
LEFRANC ET AL.: "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and I superfamily V-like domains", DEV. COMP. IMMUNOL, vol. 27, 2003, pages 55 - 77, XP055585227, DOI: 10.1016/S0145-305X(02)00039-3
LEFRANC ET AL.: "The IMGT unique numbering for immunoglobulins, T cell Receptors and Ig-like domains", THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LONBERG, HANDB. EXP. PHARMACOL., vol. 181, 2008, pages 69 - 97
LONBERG, NAT. BIOTECHNOL., vol. 23, no. 9, 2005, pages 1117 - 25
MADONNA ET AL: "The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 13, 5 July 2019 (2019-07-05), Basel, CH, pages 3318, XP055899728, ISSN: 1661-6596, DOI: 10.3390/ijms20133318 *
OSBOURN ET AL., NAT. BIOTECHNOL., vol. 16, 1998, pages 778
RAPP ET AL., AM. J. CLIN. DERM., vol. 7, 2006, pages 185 - 12
SODING, BIOINFORMATICS, vol. 21, no. 7, 2005, pages 951 - 960
TAN ET AL., J. CUTAN. MED. SURG., vol. 11, no. 6, 2007, pages 211 - 216
TOWNE ET AL., J. BIOL. CHEM., vol. 279, no. 14, 2004, pages 13677 - 13688
ZAENGLIN ET AL., J. AM. ACAD. DERM., vol. 74, no. 5, 2016, pages 945 - 973

Similar Documents

Publication Publication Date Title
JP6842488B2 (ja) 抗ｃｄ４０抗体およびその使用
RU2563830C2 (ru) Лечение остеоартрита и боли
RU2570639C2 (ru) Терапевтические dll4-связывающие белки
JP2016029027A (ja) プロスタグランジンｅ２結合タンパク質およびこの使用
JP2012507294A (ja) ヒトｉｌ−４受容体に対する高親和性ヒト抗体
KR20120135419A (ko) 치료학적 ｄｌｌ４ 결합 단백질
JP2010505418A (ja) ヒトｉｌ−４受容体に対する高親和性ヒト抗体
KR20160067846A (ko) Nav1.7 항체 및 그의 사용 방법
US20230035798A1 (en) Antigen Binding Molecules That Bind LIGHT
US20150203592A1 (en) Compositions and methods for treating osteoarthritis
WO2022011324A1 (fr) Traitement de maladies inflammatoires faisant appel à des anticorps anti-facteur tissulaire
WO2022150644A1 (fr) Thérapie contre l&#39;acné par récepteur de l&#39;interleukine 36 (il-36r)
WO2022150642A1 (fr) Thérapie anti-récepteur de l&#39;interleukine 36 (il-36r) contre la maladie de verneuil
CN110461875B (zh) 结合light的抗原结合分子
US20230272092A1 (en) Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (fr) Thérapie anti-récepteur de l&#39;interleukine 36 (il-36r) pour traiter la toxicité cutanée
TW202342517A (zh) 使用抗組織因子抗體之炎性疾病治療
WO2024050457A1 (fr) Agents de liaison à sars-cov-2 et utilisations associées
TW202035457A (zh) 靶向cd137的抗體及其使用方法
NZ793343A (en) Anti- LAG-3 antibodies and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22701491

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22701491

Country of ref document: EP

Kind code of ref document: A1